We are live on ! Find out more
DFTX

Definium Therapeutics

181 hedge funds and large institutions have $271M invested in Definium Therapeutics in 2025 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 57 increasing their positions, 49 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more call options, than puts

Call options by funds: $6.9M | Put options by funds: $4.38M

16% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 49

13% more capital invested

Capital invested by funds: $241M → $271M (+$30.5M)

0.71% more ownership

Funds ownership: 54.61%55.32% (+0.71%)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

5% less funds holding

Funds holding: 190181 (-9)

33% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 27

Holders
181
Holders Change
-9
Holders Change %
-4.74%
% of All Funds
2.38%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
18
Increased
57
Reduced
49
Closed
27
Calls
$6.9M
Puts
$4.38M
Net Calls
+$2.52M
Net Calls Change
-$1.47M

DFTX Hedge Fund Activity: Q2 2025 in Review

181 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q2 2025, worth a combined $271M — up 13% from $241M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of DFTX and 18 opened new positions — a net loss of 9 holders — while 49 trimmed existing stakes and 57 added.

The largest buyer was Marshall Wace, adding an estimated $5.45M. The largest seller was Octagon Capital Advisors, cutting an estimated $5.84M.

  • 181 institutional investors held Definium Therapeutics (DFTX) as of Q2 2025, down from 190 in Q1 2025.
  • Funds reported $271M of Definium Therapeutics stock for Q2 2025, up 13% quarter-over-quarter.
  • 18 funds opened new Definium Therapeutics positions in Q2 2025 and 27 closed out, a net change of -9 holders.
  • The largest Definium Therapeutics buyer in Q2 2025 was Marshall Wace, an estimated $5.45M added.
  • The largest Definium Therapeutics seller in Q2 2025 was Octagon Capital Advisors, an estimated $5.84M sold.

Based on aggregated 13F filings for Q2 2025.